All In Biotech

NDA 215446 · Shionogi

Radicava Ors

Edaravone · Oral

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: May 12, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

May 12, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

69

18 Phase 3, 6 recruiting

FAERS reports

1,604

1,191 serious, 462 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 5, 2026.

RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS). RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS). ( 1 )

Mechanism: The mechanism by which RADICAVA and RADICAVA ORS exert their therapeutic effect in patients with ALS is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 12, 2022 Original approval · Type 3 - New Dosage Form · priority review OrphanLetterLabelReview
1 products under this application
  • RADICAVA ORS · EDARAVONE 105MG/5ML · SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Edaravone" as an intervention, any sponsor and status, largest first.

All 69 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death212
  • cerebral infarction99
  • amyotrophic lateral sclerosis84
  • disease progression74
  • drug ineffective63
  • off label use53
  • dyspnoea51
  • muscular weakness50
  • fatigue45
  • pneumonia45
  • diarrhoea44
  • condition aggravated41

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20053
20064
20073
20082
20094
20101
20113
201230
201325
201418
201522
201621
201745
201849
201976
202042
202156
2022103
2023194
2024363
2025319
2026218

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Radicava Ors (Edaravone)

2024 spending

$376M

Beneficiaries

3,530

26,703 claims

Per beneficiary

$106,432

$274.41 per unit

View as table
YearSpending
2020$0
2021$0
2022$88,869,916
2023$293,678,844
2024$375,705,708

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 127 on PubMed

Sponsor: Shionogi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.